Tandem Diabetes Care Stock Today
| TNDM Stock | USD 35.15 2.38 6.34% |
Performance4 of 100
| Odds Of DistressLess than 25
|
Tandem Diabetes is selling at 35.15 as of the 17th of January 2025; that is 6.34 percent decrease since the beginning of the trading day. The stock's lowest day price was 34.33. Tandem Diabetes has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Note, on September 11, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Tandem Diabetes Care's common stock.
Business Domain Health Care Equipment & Services | IPO Date 14th of November 2013 | Category Healthcare | Classification Health Care |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. The company has 65.68 M outstanding shares of which 7.09 M shares are at this time shorted by private and institutional investors with about 5.7 trading days to cover. More on Tandem Diabetes Care
Moving against Tandem Stock
Tandem Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Brian Hansen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Drugs (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, SP Small-Cap 600, NASDAQ Composite Total, NASDAQ Health Care, Drugs, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTandem Diabetes can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tandem Diabetes' financial leverage. It provides some insight into what part of Tandem Diabetes' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tandem Diabetes Care (TNDM) is traded on NASDAQ Exchange in USA. It is located in 12400 High Bluff Drive, San Diego, CA, United States, 92130 and employs 2,400 people. Tandem Diabetes is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.46 B. Tandem Diabetes Care conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 65.68 M outstanding shares of which 7.09 M shares are at this time shorted by private and institutional investors with about 5.7 trading days to cover.
Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47.
Check Tandem Diabetes Probability Of Bankruptcy
Ownership AllocationThe majority of Tandem Diabetes Care outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tandem Diabetes to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tandem Diabetes Care. Please pay attention to any change in the institutional holdings of Tandem Diabetes Care as this could imply that something significant has changed or is about to change at the company. On September 11, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Tandem Diabetes Care's common stock.
Check Tandem Ownership Details
Tandem Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-09-30 | 1.4 M | |
| Stephens Inv Mgmt Group Llc | 2024-09-30 | 1.3 M | |
| Park West Asset Management Llc | 2024-09-30 | 1.1 M | |
| Divisadero Street Capital Management, Lp | 2024-09-30 | 1.1 M | |
| First Light Asset Management, Llc | 2024-09-30 | 1 M | |
| Chicago Capital, Llc | 2024-09-30 | 1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 992.7 K | |
| Next Century Growth Investors Llc | 2024-09-30 | 982.7 K | |
| Hhg Plc | 2024-09-30 | 913.5 K | |
| Blackrock Inc | 2024-09-30 | 11.1 M | |
| Vanguard Group Inc | 2024-09-30 | 7.4 M |
Tandem Diabetes Historical Income Statement
Tandem Stock Against Markets
Tandem Diabetes Corporate Management
| Tom Fox | Chief Officer | Profile | |
| Susan Morrison | Chief Admin. Officer | Profile | |
| Mark Novara | Executive Officer | Profile | |
| Ross Sylvia | VP Marketing | Profile | |
| David Esq | Transitional Advisor | Profile | |
| Jordan MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.